A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

NCT06499688 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
529
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Chongqing Claruvis Pharmaceutical Co., Ltd.